Biogroup - comment

Our projections were broadly accurate, with revenue €7m higher and EBITDA €4m higher than reported. However, we continue to find

Tomás Mannion5 December 2025BIOGROUP

Please find our updated analysis on BioGroup here.

Given the spread widening during the Summer, we have re-visited the investment case for a long trade. The sub bonds are attractive, and given that

Tomás Mannion29 September 2025BIOGROUP

BioGroup - comment

BioGroup shareholders have informally appointed Centerview Partners to explore options for an exit. This appears to be at the

Tomás Mannion24 September 2025BIOGROUP

Biogroup - comment

The new format of HY conference calls, which gives preference to typed questions rather than live telephone inquiries, has resulted in

Tomás Mannion17 September 2025BIOGROUP

BioGroup - comment

BioGroup released its Q2 results yesterday. However, with minimal commentary provided in the announcement and the earnings call not

Tomás Mannion12 September 2025BIOGROUP

Biogroup, Cerba, Clariane - comment

One of the sources of the turmoil in French politics is the 2026 Budget and the debt reduction plans used to narrow France’s deficit from its current

Tomás Mannion9 September 2025CERBA, BIOGROUP, CLARIANE

BioGroup Live Discussion is now available on Biogroup’s page, here.

Martha Felix3 July 2025BIOGROUP

BioGroup - Having done the cashflows

Please find our initiation on BioGroup here.

Many of you have asked us to look at BioGroup following our detailed analysis on Cerba. Although BioGroup operate and is subject to

Tomás Mannion26 June 2025BIOGROUP